PDEX Stock Risk & Deep Value Analysis
Pro-Dex Inc
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About PDEX Stock
We analyzed Pro-Dex Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PDEX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
PDEX Risk Analysis & Red Flags
What Could Go Wrong
Despite a strong balance sheet, Pro-Dex's core business lacks the disruptive innovation or exponential scalability required for significant market expansion, limiting its long-term growth ceiling and making it vulnerable to saturation in its niche market without a major strategic pivot.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Lack of explicit growth catalysts for 10x potential.
- ⚠
Reliance on a contract manufacturing model that inherently limits exponential scalability.
- ⚠
Minimal analyst coverage or institutional interest, suggesting low growth expectations.
- ⚠
Forward P/E higher than trailing P/E suggests analysts expect slower near-term EPS growth, given current price implies ~20x TTM P/E ($54.43 / $2.70).
Upcoming Risk Events
- 📅
Failure to meet modest earnings expectations for Q3/Q4 2026
- 📅
Slowdown in capital expenditures or innovation within the medical/dental device sector
- 📅
Loss of a significant contract manufacturing client
When to Reconsider
- 🚪
Exit if quarterly revenue declines year-over-year for two consecutive quarters.
- 🚪
Sell if gross margin falls below 35% indicating pricing pressure or inefficiency.
- 🚪
Exit if management announces a significant strategic change that dilutes core business focus without clear growth path.
Unlock PDEX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Pro-Dex Inc (PDEX) Do?
Market Cap
$171.20M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
179
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Visit Pro-Dex Inc WebsiteInvestment Thesis
Pro-Dex offers investors a financially sound, profitable, and stable small-cap company operating in a critical niche within the medical and dental device sectors. While lacking 10x growth potential, its strong balance sheet, consistent profitability, and specialized expertise provide a defensive investment that can deliver modest, consistent returns within a diversified portfolio.
Is PDEX Stock Undervalued?
Unlock the full AI analysis for PDEX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PDEX Price Targets & Strategy
12-Month Target
$60.00
Bull Case
$65.00
Bear Case
$45.00
Valuation Basis
20x forward P/E on estimated FY26 EPS of $3.00, reflecting current implied multiple and modest growth.
Entry Strategy
Given current valuation and stable business, consider dollar-cost averaging on dips towards $50-$52. No specific technical levels provided in research.
Exit Strategy
Take profit at $60-$65 range. Set a stop-loss around $45 if fundamental performance deteriorates or sector-specific headwinds emerge.
Portfolio Allocation
2% for moderate risk tolerance, primarily as a stable, quality holding rather than a growth play.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PDEX Financially Healthy?
Valuation
P/E Ratio
15.10
Forward P/E
14.20
Profitability
Gross Margin
28.29%
Operating Margin
15.74%
Net Margin
15.73%
Return on Equity
29.25%
Revenue Growth
18.19%
EPS
$3.40
Balance Sheet
Current Ratio
3.23
Quick Ratio
1.69
Debt/Equity
0.42
Other
Beta (Volatility)
-0.05
Does PDEX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
Pro-Dex's moat is durable due to the specialized nature of its products, the high R&D and regulatory hurdles involved, and the deep integration with client product development, making it costly and risky for clients to switch suppliers. Its specific expertise is not easily replicated.
Moat Erosion Risks
- •Technological obsolescence of its current instrument platforms.
- •Major clients insourcing manufacturing capabilities or shifting to competitors.
- •Increased competition from other highly specialized contract manufacturers.
PDEX Competitive Moat Analysis
Sign up to see competitive advantages
PDEX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (due to specialized niche and limited public profile)
Institutional Sentiment
Neutral (data unavailable in research, suggesting limited institutional coverage or significant activity)
Insider Activity (Form 4)
CFO Alisha K. Charlton's base salary increased to $257,000, effective post-March 23, 2026. No Form 4 filings for insider share buys/sells reported in the last 90 days.
Options Flow
Normal options activity (no specific data provided, indicates no unusual institutional positioning)
Earnings Intelligence
Next Earnings
Estimated May 7, 2026 (Q4 2026 fiscal year)
Surprise Probability
Low (stable business, less prone to dramatic swings)
Historical Earnings Pattern
Historically, Pro-Dex likely exhibits stable stock price reactions to earnings, with modest movements unless there's a significant deviation from expectations or a strategic announcement.
Key Metrics to Watch
Competitive Position
Top Competitor
ITGR (Integer Holdings Corp)
Market Share Trend
Stable (likely maintaining its niche position rather than aggressively gaining or losing market share)
Valuation vs Peers
Trading at an implied TTM P/E of ~20.16, which may be at a slight premium to some pure-play contract manufacturers but a discount to higher-growth medical technology firms.
Competitive Advantages
- •Specialized design and manufacturing expertise in miniature, powered rotary instruments.
- •Strong relationships with key medical and dental device clients, leading to high switching costs.
- •Adherence to stringent regulatory and quality standards (e.g., FDA, ISO).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PDEX Stock Higher?
Near-Term (0-6 months)
- •Q3 2026 Earnings (announced April 29, 2026)
- •Q4 2026 Fiscal Year Earnings (expected May 7, 2026)
Medium-Term (6-18 months)
- •Potential new specialized contract wins or expanded relationships with existing clients
- •Sustained demand in the dental and medical device markets
Long-Term (18+ months)
- •Continued reliance of larger medical device companies on specialized contract manufacturers
- •Introduction of next-generation surgical/dental instruments
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PDEX?
- ✓
Sustained organic revenue growth acceleration (e.g., above 20% YoY for several quarters).
- ✓
Announcement of a significant new partnership or a major expansion into a new, high-growth medical sub-segment.
- ✓
Evidence of margin expansion driven by new, higher-value product lines.
Bull Case Analysis
See what could go right with Premium
Competing with PDEX
See how Pro-Dex Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Pro-Dex Inc PDEX | $171.2M | 1.4 | 15.1 | $66.6M | 15.7% | 18.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Pro-Dex Inc Makes Money
Pro-Dex Inc. is a company that designs, develops, and manufactures highly specialized, miniature, and precision-powered rotary instruments, primarily for the medical and dental industries. They essentially operate as a contract manufacturer and engineering partner, providing custom solutions and components to other medical and dental device companies. Their revenue is generated by selling these unique instruments and offering associated design and development services, leveraging their niche expertise and strict adherence to industry regulations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Pro-Dex Inc (PDEX)?
As of April 20, 2026, Pro-Dex Inc has a DVR Score of 1.4 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Pro-Dex Inc?
Pro-Dex Inc's market capitalization is approximately $171.2M. The company operates in the Healthcare sector within the Medical Instruments & Supplies industry.
What ticker symbol does Pro-Dex Inc use?
PDEX is the ticker symbol for Pro-Dex Inc. The company trades on the NCM.
What is the risk level for PDEX stock?
Our analysis rates Pro-Dex Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PDEX?
Pro-Dex Inc currently has a price-to-earnings (P/E) ratio of 15.1. This is in line with broader market averages.
Is Pro-Dex Inc's revenue growing?
Pro-Dex Inc has reported revenue growth of 18.2%. The company is showing strong top-line momentum.
Is PDEX stock profitable?
Pro-Dex Inc has a profit margin of 15.7%. The company is profitable but margins are modest.
How often is the PDEX DVR analysis updated?
Our AI-powered analysis of Pro-Dex Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PDEX (Pro-Dex Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.